TG Therapeutics, Inc. Presents Pre-clinical Data on IRAK4 Compounds at the American Association for Cancer Research Annual Meeting

Loading...
Loading...
TG Therapeutics, Inc.
TGTX
today announced the first presentation of preclinical data demonstrating single agent and combination activity of two of the Company's IRAK4 inhibitor compounds under development. Both compounds are potent inhibitors of IRAK4 with single-digit nanomolar potency. This pre-clinical data was presented yesterday at the 106th Annual Meeting of the American Association for Cancer Research (AACR), held in Philadelphia, PA. The data demonstrated that both IRAK4 inhibitors not only inhibited cell proliferation but also induced apoptosis as single agents in various B-cell lymphoma cell lines, potentially elucidating the mechanism of action of and clinical rationale for IRAK4 inhibition. In addition, both compounds demonstrated marked synergy when combined with the novel targeted kinase inhibitors TGR-1202, the Company's proprietary PI3K delta inhibitor, and the BTK inhibitor, ibrutinib. A copy of the presentation is available on the Publications page, located within the Pipeline section of the Company's website at www.tgtherapeutics.com.
Posted In: NewsFDAPress Releases
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...